8-K ·Filed May 7, 2026

VTRS

Viatris Inc
BULLISH
Impact 7/10
Horizonweeks Processed4mo ago SEC0001792044-26-000025
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong Q1 beat and reaffirmed guidance reinforce the narrative of operational improvement and cost savings from the enterprise-wide strategic review. Traders should watch upcoming PDUFA dates (MR-141 for presbyopia in October, low-dose estrogen patch in July) and the March 2026 Investor Event for long-term targets.

DirectionBullish
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
VTRS ▲ +1.38% at T+60d
LONG call ✓ call won +1.38% · α vs SPY -2.45% · entry $17.39 → $17.63
Entry anchored
May 7, 2026
via day open
T+1d
-1.27%
call -1.27% · α -2.10%
$17.17
settled 5mo ago
T+5d
-0.12%
call -0.12% · α -1.62%
$17.37
settled 5mo ago
T+20d
-10.52%
call -10.52% · α -13.66%
$15.56
settled 4mo ago
T+60d
+1.38%
call +1.38% · α -2.45%
$17.63
settled 8w ago

Price Chart

Loading chart...

Executive Summary

Viatris reported Q1 2026 adjusted EPS of $0.59, 18% above consensus of $0.50, and revenue of $3.52B, 5% above consensus of $3.36B. Results were driven by strong growth in Greater China and brands, with adjusted EBITDA up 10% operationally. The company reaffirmed its 2026 guidance, signaling confidence in its turnaround and cost-savings plan.

Key Financial Metrics

EPS
$0.59
est $0.50 · +18.0%
Revenue
$3.5B
est $3.4B · +4.7% · +8.1% YoY
Rating
strong beat
Guidance
$14,450M - $14,950M
maintained
Free Cash Flow
$348.4M
Gross Margin
32.9%

Key Facts

  • Q1 2026 total revenues of $3.517B, up 8% reported (3% operational) YoY
  • Adjusted EPS of $0.59 vs consensus $0.50 (18% beat); GAAP EPS $0.15
  • Adjusted EBITDA of $1.05B, up 14% reported (10% operational) YoY
  • Reaffirmed 2026 guidance: revenue $14.45-14.95B, adjusted EBITDA $4.15-4.45B, adjusted EPS $2.33-2.47
  • Greater China net sales up 22% reported (18% operational)
  • Fire at Nashik facility caused $71.9M write-off in Q1; expects to resume operations in April 2026

Financial Impact

Adjusted EPS beat by 18% ($0.59 vs $0.50); revenue beat by 5% ($3.517B vs $3.36B); guidance reaffirmed

revenueepsadjusted_ebitda

Risk Factors

  • Restructuring and fire-related costs could weigh on GAAP profitability
  • Generic competition and pricing pressure in developed markets
  • Execution risk on $700-850M restructuring program

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (18 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001792044-26-000025
Document: vtrs-20260507.htm0001792044-26-000025
Document: 0001792044-26-000025-index-headers.html0001792044-26-000025
Document: 0001792044-26-000025-index.html0001792044-26-000025
Document: 0001792044-26-000025.txt0001792044-26-000025
8-K Data (Synthetic)0001792044-26-000025
12 reports for VTRS
Performance horizon
50% Hit rate 2 of 4 directional calls best @ T+60▲ +17.24%May 4, 2026
Filters
Rows
Reports for VTRS — sortable, filterable
TypeNow
Aug 6, 2026
8w ago
8-K
BULLISH ★ 7/10
$16.29 $16.94▲ +3.99%▲ +3.39%$17.60 (+8.04%)
Jun 25, 2026
14w ago
144
NEUTRAL ★ 3/10
$16.33 $17.28▲ +5.82%▲ +4.56%$17.60 (+7.78%)
Jun 18, 2026
15w ago
8-K
NEUTRAL ★ 3/10
$15.38 $17.29▲ +12.42%▲ +12.57%$17.60 (+14.43%)
Jun 15, 2026
15w ago
8-K
NEUTRAL ★ 3/10
$16.04 $16.31▲ +1.68%▲ +1.48%$17.60 (+9.73%)
May 13, 2026
20w ago
Court Ruling
BULLISH ★ 7/10
$17.37 $16.31▼ −6.10%▼ −5.49%$17.60 (+1.32%)
May 7, 2026
21w ago
8-K
BULLISH ★ 7/10
$17.39 $15.56▼ −10.52%▼ −13.66%$17.60 (+1.21%)
May 4, 2026
21w ago
8-K
NEUTRAL ★ 3/10
$15.52 $15.69▲ +1.10%▼ −3.86%$17.60 (+13.40%)
May 4, 2026
21w ago
Court Ruling
NEUTRAL ★ 2/10
$15.20 $15.69▲ +3.22%▼ −2.56%$17.60 (+15.79%)
May 4, 2026
21w ago
Court Ruling
BULLISH ★ 4/10
$15.20 $15.69▲ +3.22%▼ −2.56%$17.60 (+15.79%)
Apr 13, 2026
24w ago
Court Ruling
MIXED ★ 6/10
$13.83 $16.92▲ +22.34%▲ +14.59%$17.60 (+27.26%)
Showing 10 of 12

US Market Status

Market Closed — Opens Mon (64h 10m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access